Xbrane Biopharma: Setback From the FDA - Redeye

Redeye feels disappointed following FDA requesting complimentary information ahead of accepting the BLA for Xlucane. The available information is scarce at this point, and due to the lack of information on the matter, we expect the share price to decline sharply, possibly in the magnitude of ~20-30%. We will return with a more elaborate comment once more information is available to assess the significance of the delayed launch in the US.

Länk till analysen i sin helhet: https://www.redeye.se/research/843920/xbrane-biopharma-setback-from-the-fda?utm_source=finwire&utm_medium=RSS